Streetbeat News

Stock Prices

J

Analysts have mixed views on Jacobs Solutions (NYSE:J), with recent ratings ranging from bullish to somewhat bullish. The average 12-month price target is $155.5, reflecting a slight increase from the previous target. Jacobs Solutions, a global provider of various services, has shown notable revenue growth and profitability, although its ROE is below industry averages. The company's financial health is solid, with a strong ROA and a conservative debt approach.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 6:00 pm

IPG

Interpublic Gr of Cos (NYSE:IPG) is scheduled to release its quarterly earnings report on February 8, 2024. Analysts predict an EPS of $1.13. The company's past earnings performance shows mixed results with both misses and beats in previous quarters. Shares are currently trading at $32.99, reflecting a 12.86% decline over the last year. Investors are keenly awaiting the report, especially the company's guidance for future quarters, which could significantly impact the stock price.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 6:00 pm

FERG

Over the past 5 years, Ferguson (NYSE:FERG) has outperformed the market with an annualized return of 22.88%, turning a $100 investment into $280.22 today. Ferguson's market capitalization stands at $39.42 billion.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 6:00 pm

AJG

Over the past 20 years, Arthur J. Gallagher (NYSE:AJG) has outperformed the market with an annualized return of 10.18%, turning a $100 investment into $716.38 today. The company currently has a market capitalization of $50.72 billion.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 6:00 pm

UHS

Universal Health Services (NYSE:UHS) has seen a decrease in short interest, with the short percent of float dropping 8.85% since the last report, now at 3.5% of all shares available for trading. This decline in short interest could indicate a more bullish sentiment towards UHS among traders. The company's short interest is also lower than its peer group average of 5.12%, suggesting it may be performing better than its peers in this aspect.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 6:00 pm

XYL

Six analysts have recently updated their evaluations of Xylem (NYSE:XYL), showing a mix of bullish to indifferent sentiments. The average 12-month price target for XYL has increased to $129.5, up 7.74% from $120.20. Analyst actions include rating upgrades and price target adjustments, reflecting positive market conditions and company performance. Xylem's financial performance shows strong revenue growth but challenges in profitability and asset utilization. The company's market capitalization and debt management are highlighted as strengths.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 6:00 pm

LGIH

LGI Homes (NYSE:LGIH) has seen a 3.9% decrease in short interest, now at 2.17 million shares or 12.57% of float, taking 15.44 days on average to cover. This decline in short interest could indicate a more bullish sentiment towards LGIH compared to its peers, where the average short interest is 4.81% of float.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 6:00 pm

BG

Bunge Global's (NYSE:BG) short interest has increased by 23.45% since the last report, with 4.78 million shares sold short, representing 4.37% of its float. This indicates a bearish market sentiment, although it doesn't necessarily predict a near-term price drop. Compared to its peers, BG has a higher short interest percentage of float (4.37% vs. the peer group average of 1.89%), suggesting more bearish sentiment towards BG than its peers.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 6:00 pm

RGNX

REGENXBIO Inc (NASDAQ:RGNX) reported positive interim results from the Phase 1/2 AFFINITY DUCHENNE trial of RGX-202 for Duchenne muscular dystrophy and from the Phase 1/2/3 CAMPSIITE trial of RGX-121 for Mucopolysaccharidosis Type II (MPS II). RGX-202 showed no serious adverse events and significant microdystrophin expression and CK level reduction, indicating potential clinical improvement. RGX-121 met its primary endpoint with significant reductions in a key biomarker of brain disease activity in MPS II patients. REGENXBIO plans pivotal trials and FDA marketing applications for both treatments in 2024. RGNX shares surged 11.80% to $14.89.

Portfolio Pulse from Vandana Singh

February 07, 2024 | 5:59 pm

XPO

XPO Inc (NYSE:XPO) reported a 6% year-over-year revenue growth for Q4 fiscal 2023, reaching $1.94 billion and surpassing the consensus of $1.92 billion. Despite a decrease in adjusted EPS from $0.98 to $0.77, it beat the consensus of $0.62. Operating income significantly improved to $119 million from $4 million a year ago, with a slight increase in adjusted EBITDA to $264 million. The North American Less-Than-Truckload segment saw an 8.6% revenue increase, while European Transportation revenue grew by 2%. The company ended the quarter with $412 million in cash and expects a gross capex of $700 million to $800 million for 2024. XPO shares surged 17.46% to $115.17.

Portfolio Pulse from Akanksha Bakshi

February 07, 2024 | 5:56 pm